Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the 12 Best Genomics Stocks to Invest In.
Cathie Wood’s ARK Investment acquired 755,000 shares of Recursion Pharmaceuticals, Inc. on December 19, 2025, according to a report published in TheFly.
On December 17, 2025, JPMorgan raised Recursion Pharmaceuticals, Inc. from Neutral to Overweight, with a price objective of $11 instead of $10. According to the firm, REC-4881 proved solid and long-lasting effectiveness in treating familial adenomatous polyposis.
The analyst informs investors in a research note that REC-4881’s addressable market is now larger than anticipated, providing explosive potential. JPMorgan has a 60% chance of success and peak revenues of more than $1 billion. Furthermore, per JPMorgan, Recursion Pharmaceuticals, Inc.’s CDK7 inhibitor REC-617 has proven early anti-tumor effectiveness in platinum-resistant ovarian cancer.
The company has reiterated its 2025 forecast with an expense base of less than $450 million, which does not include any inflows from partnerships. The overall forecast for 2026 has been maintained at less than $390 million. It is also anticipated that the cash position will sustain operations until the end of 2027 without the need for further funding.
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology business.
READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.
Disclosure. None
